Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
McMaster University, Hamilton, Ontario, Canada.
J Urol. 2016 Jul;196(1):95-100. doi: 10.1016/j.juro.2015.12.082. Epub 2015 Dec 31.
We assessed prognostic factors, treatments and outcomes in patients with teratoma with malignant transformation, a rare occurrence among germ cell tumors.
Data on patients diagnosed with teratoma with malignant transformation between June 1981 and August 2014 were collected across 5 referral centers. Chemotherapy was dichotomized as based on germ cell tumor or teratoma with malignant transformation. Cox analyses were done to evaluate prognostic factors of overall survival, the primary end point. Each factor was evaluated in a univariable model. Forward stepwise selection was used to construct an optimal model.
Among 320 patients the tumor primary site was gonadal in 287 (89.7%), retroperitoneal in 17 (5.3%) and mediastinal in 16 (5%). Teratoma with malignant transformation and germ cell tumor were diagnosed concurrently in 130 patients (40.6%). A total of 49 patients (16.8%) initially presented with clinical stage I. The remaining patients were at good (123 or 42.3%), intermediate (42 or 14.4%) and poor (77 or 26.5%) risk for metastasis according to IGCCCG (International Germ Cell Cancer Collaborative Group). First line chemotherapy was given for germ cell tumor in 159 patients (49.7%), chemotherapy for teratoma with malignant transformation was performed in 14 (4.4%) and only surgery was done in 147 (45.9%). Median followup was 25.1 months (IQR 5.4-63.8). Five-year overall survival was 83.4% (95% CI 61.3 to 93.5) in patients with clinical stage I and it was also worse than expected in those with metastasis. On multivariable analyses nonprimitive neuroectodermal tumor histology (overall p = 0.004), gonadal primary tumor (p = 0.005) and fewer prior chemotherapy regimens (p <0.001) were independent predictors of better overall survival. Chemotherapy was not independently prognostic.
Less heavily pretreated teratoma with malignant transformation with a gonadal primary tumor and nonprimitive neuroectodermal tumor histology appears to be associated with longer overall survival. Generally, teratoma with malignant transformation had a worse prognosis than germ cell tumor. Uncertainties persist regarding optimal chemotherapy.
我们评估了畸胎瘤恶性转化患者的预后因素、治疗方法和结局,畸胎瘤恶性转化是生殖细胞肿瘤中罕见的一种情况。
在五个转诊中心收集了 1981 年 6 月至 2014 年 8 月期间诊断为畸胎瘤恶性转化的患者的数据。根据生殖细胞瘤或畸胎瘤恶性转化,将化疗分为两类。使用 Cox 分析评估总生存率的预后因素,这是主要终点。在单变量模型中评估每个因素。采用逐步向前选择构建最佳模型。
在 320 名患者中,肿瘤的原发部位为性腺 287 例(89.7%),腹膜后 17 例(5.3%),纵隔 16 例(5%)。畸胎瘤恶性转化和生殖细胞瘤同时诊断 130 例(40.6%)。49 例(16.8%)患者最初表现为临床 I 期。其余患者根据 IGCCCG(国际生殖细胞瘤癌症协作组)标准,转移的风险良好(123 例,42.3%)、中等(42 例,14.4%)和差(77 例,26.5%)。159 例(49.7%)患者接受生殖细胞瘤一线化疗,14 例(4.4%)患者接受畸胎瘤恶性转化化疗,147 例(45.9%)患者仅行手术治疗。中位随访时间为 25.1 个月(IQR 5.4-63.8)。临床 I 期患者的 5 年总生存率为 83.4%(95%CI 61.3-93.5),转移患者的生存率也低于预期。多变量分析显示,非原始神经外胚层肿瘤组织学(总体 p = 0.004)、性腺原发性肿瘤(p = 0.005)和较少的化疗方案(p <0.001)是总生存率更好的独立预测因素。化疗不是独立的预后因素。
原发于性腺、组织学为非原始神经外胚层肿瘤且预处理较少的畸胎瘤恶性转化似乎与总生存率延长有关。一般来说,畸胎瘤恶性转化的预后比生殖细胞瘤差。关于最佳化疗仍存在不确定性。